Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Conditions
Brief summary
The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
Detailed description
Primary Objective: Determine the maximum (no greater than 125 mg) dose of infigratinib used in combination with the FDA-approved dose and schedule of tamoxifen (Cohort 1) in terms of the number of dose-limiting toxicities observed in the first 2 cycles of therapy in subjects with hormone receptor-positive, HER2-negative advanced breast cancer. Secondary Objective: * Estimate the incidence of treatment-emergent adverse events (serious and non-serious). * Estimate the objective tumor response rate (ORR) in subjects with measurable disease. * Estimate the progression-free survival (PFS). * Estimate the durable clinical benefit rate.
Interventions
DRUGInfigratinib
Oral dose
DRUGTamoxifen
Oral Dose
DRUGOmnipaque 350
IV contrast agent
DRUGIopamidol
IV contrast agent
DIAGNOSTIC_TESTComputed tomography (CT)
Computed tomography (CT) to assess disease state using Iopamidol and/or Omnipaque 350.
Sponsors
Jennifer Lee Caswell-Jin
National Cancer Institute (NCI)
QED Therapeutics, a BridgeBio company
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* History of biopsy proven ER positive and/or PR positive, HER2 negative breast cancer and radiographic evidence of metastatic disease, or locally recurrent unresectable disease. ER positivity and PR positivity are defined as ≥ 1% cells staining positive by immunohistochemistry. HER2 negativity is defined by immunohistochemistry (IHC) or Fluorescence in situ hybridization (FISH). * Cancer subtype: Predicted integrative subtype classification of IC2 or IC6 according classifier on targeted sequencing data from FoundationOne. * Evaluable or measurable disease, by cohort. Cohort 1 only: Evaluable or measurable disease, as defined by RECIST v1.1. Bone only disease is acceptable. Cohort 2 only: Measurable disease, as defined by RECIST v1.1. * ≥ 18 years old * Eastern Cooperative Oncology Group (ECOG) 0 to 2 * Prior cancer therapy (except for endocrine therapy, denosumab, or bisphosphonates) must be discontinued for 2 weeks prior to initiation of study drugs. Recovery from adverse events of previous cancer therapies to baseline or Grade 1 except for alopecia or stable Grade 2 neuropathy. Radiotherapy must also be completed at least 2 weeks prior to initiation of study drugs * Absolute neutrophil count (ANC) ≥ 1,000/mm3 * Platelets ≥ 75,000/mm3 * Hemoglobin ≥ 9.0 g/dL * Total bilirubin ≤ 1.8 mg/dL (unless documented Gilbert's disease) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 90 U/L * Estimated glomerular filtration rate (GFR) ≥ 45 mL/min * Phosphorus between 2.5 and 4.5 mg/dL, inclusive * Total corrected (for albumin) serum calcium between 8.5 and 10.5 mg/dL, inclusive * Amylase \< 200 U/L * Lipase \< 120 U/L * Ability to understand and the willingness to sign a written informed consent document * Agrees to take sevelamer, if indicated, and has no contraindications to use of this medication (that is: known hypersensitivity to sevelamer or component of the formulation; bowel obstruction; active bowel mucosal injury such as ulcerative colitis or gastrointestinal bleeding). * Agrees to follow low phosphate diet, if indicated * Able to swallow and retain oral medication * Women must be postmenopausal, defined as (at least one of): * ≥ 60 years of age; * amenorrhea for at least 24 months; * amenorrhea for at least 12 months with serum estradiol \< 20 pg/mL; * prior bilateral oophorectomy; OR * treatment with a luteinizing hormone (LH) releasing hormone agonist (such as goserelin acetate or leuprolide acetate) initiated at least 28 days prior to study enrollment. * Women being treated with a LH releasing agonist but who are otherwise of childbearing potential (did not undergo total hysterectomy or bilateral tubal ligation at least 6 weeks before first dose of study drug) must have a negative pregnancy test within 7 days of the first dose of study drug. * Women who are being treated with a LH releasing agonist but are otherwise of childbearing potential must agree to use barrier contraception or an intrauterine device while taking study drug and for 3 months following their last dose of study drug. Alternatively, total abstinence is acceptable if preferred by the subject. * Sexually active men must agree to use a condom during intercourse while taking drug and for 3 months after the last dose of the study drug and should not father a child during this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner to prevent delivery of the drug via seminal fluid.
Exclusion criteria
* History of another primary malignancy within 3 years except adequately treated in situ carcinoma of the cervix or non melanoma carcinoma of the skin or any other curatively treated malignancy that is not expected to require treatment for recurrence during the course of the study. * Neurologic symptoms related to central nervous system metastases requiring increasing doses of corticosteroids. Note that subjects with central nervous system metastases are eligible if they are on a stable corticosteroid dose for at least 2 weeks preceding study entry. * Current evidence of corneal or retinal disorder/keratopathy including, but not limited to, bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, confirmed by ophthalmologic examination. Subjects with asymptomatic ophthalmologic conditions assessed by the investigator to pose minimal risk for study participation may be enrolled in the study. * Current evidence of extensive tissue calcification including, but not limited to, the soft tissue, kidneys, intestine, myocardium, and lung with the exception of calcified lymph nodes, minor pulmonary parenchymal calcifications, and asymptomatic coronary calcification. * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib (eg, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection). * Current evidence of endocrine alterations of calcium/phosphate homeostasis, eg, parathyroid disorders, history of parathyroidectomy, tumor lysis, or tumoral calcinosis. * Currently receiving or planning during study participation to receive treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration. Subjects are not permitted to receive enzyme inducing anti epileptic drugs, including carbamazepine, phenytoin, phenobarbital, and primidone. See Appendix B for a list of prohibited concomitant medications and supplements. * Has consumed grapefruit, grapefruit juice, grapefruit hybrids, pomegranates, star fruits, pomelos, Seville oranges, or products containing juice of these fruits within 7 days prior to first dose of study drug. * Have used amiodarone within 90 days prior to first dose of study drug. * Has used medications known to prolong the QT interval and/or are associated with a risk of Torsades de Pointes (TdP) 7 days prior to first dose of study drug. See Appendix B for a list of prohibited concomitant medications and supplements. * Has used calcium or vitamin D within 3 days prior to first dose of study drug. Calcium supplementation may subsequently be used as clinically indicated (for hypocalcemia) on study. * Have clinically significant cardiac disease including any of the following: 1. Congestive heart failure requiring treatment (New York Heart Association Grade ≥ 2), left ventricular ejection fraction (LVEF) \< 50% or local lower limit of normal as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO), or uncontrolled hypertension (refer to the European Society of Cardiology and European Society of Hypertension guidelines \[Williams et al., 2018\]) 2. Presence of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade ≥ 2 ventricular arrhythmias, atrial fibrillation, bradycardia, or conduction abnormality 3. Unstable angina pectoris or acute myocardial infarction ≤ 3 months prior to first dose of study drug 4. Corrected QT interval Fredericia (QTcF) \> 470 msec (males and females). Note: If the QTcF is \> 470 msec in the first electrocardiogram (ECG), a total of 3 ECGs separated by at least 5 minutes should be performed. If the average of these 3 consecutive results for QTcF is ≤ 470 msec, the subject meets eligibility in this regard. 5. Known history of congenital long QT syndrome * Have had a recent (≤ 3 months) transient ischemic attack or stroke. * Pregnant or nursing woman. * All subject files must include supporting documentation to confirm subject eligibility. The method of confirmation can include, but is not limited to, laboratory test results, radiology test results, subject self report, and medical record review.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Dose-limiting Toxicities (DLTs) | 8 weeks | The primary outcome for this study is dose-limiting toxicities (DLTs) during the first 2 cycles of therapy. All grades per the Common Terminology Criteria for Adverse Events (CTCAE). DLT is defined as a related and clinically significant adverse event (AE), including missed doses due to a related AE. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAE) | From first dose to 30 days after the last dose of study drug (up to 94 days) | Treatment emergent adverse events (TEAEs) are defined as adverse events of any grade with initial onset or increasing in severity after the first dose of study treatment until 30 days after last dose of study drug. Pregnancy during the reporting period will be classified as a serious adverse event. |
| Objective Tumor Response Rate | From enrollment to day of scan (up to 64 days) | Objective tumor response will be assessed as achieving a Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Complete Response (CR) or a Partial Response (PR). The outcome will be reported as the number of subjects that achieve an overall response (OR) to treatment, ie, CR or PR, within 18 months of starting treatment. RECIST criteria are: * CR = Disappearance of all target lesions * PR = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR * Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions, and/or the appearance of one or more new lesion(s) * Stable disease (SD) = Small changes that do not meet any of the above criteria |
| Progression-free Survival (PFS) | up to 9 months | Progression free survival (PFS) means the participant remains alive without return or relapse of the tumor. The outcome is defined as the number of days to either progressive disease as defined per RECIST v1.1 or death. RECIST criteria are: * CR = Disappearance of all target lesions * PR = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR * Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions, and/or the appearance of one or more new lesion(s) * Stable disease (SD) = Small changes that do not meet any of the above criteria |
| Clinical Benefit Rate | 6 months | Clinical benefit (CB) is defined as achieving a Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Complete Response (CR) ; Partial Response (PR); or Stable Disease (SD). The outcome will be reported as the number of subjects that achieve CR, PR, or SD. RECIST criteria are: * CR = Disappearance of all target lesions * PR = ≥ 30% decrease in the sum of the longest diameter of target lesions * SD = Small changes that do not meet any of the above criteria * Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions, and/or the appearance of one or more new lesion(s) |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJennifer Lee Caswell-Jin
Stanford Universiy
Participant flow
Recruitment details
Enrollment was closed before any participants were enrolled in Cohort 3 (Infigratinib (75 mg) + Tamoxifen).
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: Infigratinib (100mg) + Tamoxifen In study part 1 (dose exploration), participants receive infigratinib up to 100 mg administered orally daily, 3 weeks on, 1 week off + 20 mg/day tamoxifen | 3 |
| Cohort 2: Infigratinib (125mg) + Tamoxifen In study part 1 (dose exploration), participants receive infigratinib up to 125 mg administered orally daily, 3 weeks on, 1 week off + 20 mg/ day tamoxifen | 1 |
| Total | 4 |
Baseline characteristics
| Characteristic | Cohort 1: Infigratinib (100mg) + Tamoxifen | Cohort 2: Infigratinib (125mg) + Tamoxifen | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants | 1 Participants | 3 Participants |
| Age, Continuous | 55.2 years STANDARD_DEVIATION 9.6 | 38.5 years | 53.9 years STANDARD_DEVIATION 13 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 1 Participants | 3 Participants |
| Region of Enrollment United States | 3 Participants | 1 Participants | 4 Participants |
| Sex: Female, Male Female | 3 Participants | 1 Participants | 4 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 1 |
| other Total, other adverse events | 3 / 3 | 1 / 1 |
| serious Total, serious adverse events | 1 / 3 | 0 / 1 |
Outcome results
Primary
Number of Dose-limiting Toxicities (DLTs)
The primary outcome for this study is dose-limiting toxicities (DLTs) during the first 2 cycles of therapy. All grades per the Common Terminology Criteria for Adverse Events (CTCAE). DLT is defined as a related and clinically significant adverse event (AE), including missed doses due to a related AE.
Time frame: 8 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Number of Dose-limiting Toxicities (DLTs) | 0 DLTs |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Number of Dose-limiting Toxicities (DLTs) | 0 DLTs |
Secondary
Clinical Benefit Rate
Clinical benefit (CB) is defined as achieving a Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Complete Response (CR) ; Partial Response (PR); or Stable Disease (SD). The outcome will be reported as the number of subjects that achieve CR, PR, or SD. RECIST criteria are: * CR = Disappearance of all target lesions * PR = ≥ 30% decrease in the sum of the longest diameter of target lesions * SD = Small changes that do not meet any of the above criteria * Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions, and/or the appearance of one or more new lesion(s)
Time frame: 6 months
Population: Participants who completed at least 6 treatment cycles are included in the analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Clinical Benefit Rate | CR | 0 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Clinical Benefit Rate | PR | 0 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Clinical Benefit Rate | SD | 0 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Clinical Benefit Rate | CB (CR + PR +SD) | 0 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Clinical Benefit Rate | PD | 3 Participants |
Secondary
Number of Treatment Emergent Adverse Events (TEAE)
Treatment emergent adverse events (TEAEs) are defined as adverse events of any grade with initial onset or increasing in severity after the first dose of study treatment until 30 days after last dose of study drug. Pregnancy during the reporting period will be classified as a serious adverse event.
Time frame: From first dose to 30 days after the last dose of study drug (up to 94 days)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Number of Treatment Emergent Adverse Events (TEAE) | 49 adverse events |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Number of Treatment Emergent Adverse Events (TEAE) | 26 adverse events |
Secondary
Objective Tumor Response Rate
Objective tumor response will be assessed as achieving a Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Complete Response (CR) or a Partial Response (PR). The outcome will be reported as the number of subjects that achieve an overall response (OR) to treatment, ie, CR or PR, within 18 months of starting treatment. RECIST criteria are: * CR = Disappearance of all target lesions * PR = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR * Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions, and/or the appearance of one or more new lesion(s) * Stable disease (SD) = Small changes that do not meet any of the above criteria
Time frame: From enrollment to day of scan (up to 64 days)
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Objective Tumor Response Rate | PR | 0 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Objective Tumor Response Rate | PD | 3 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Objective Tumor Response Rate | OR (CR + PR) | 0 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Objective Tumor Response Rate | SD | 0 Participants |
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Objective Tumor Response Rate | CR | 0 Participants |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Objective Tumor Response Rate | SD | 1 Participants |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Objective Tumor Response Rate | CR | 0 Participants |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Objective Tumor Response Rate | PR | 0 Participants |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Objective Tumor Response Rate | OR (CR + PR) | 0 Participants |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Objective Tumor Response Rate | PD | 0 Participants |
Secondary
Progression-free Survival (PFS)
Progression free survival (PFS) means the participant remains alive without return or relapse of the tumor. The outcome is defined as the number of days to either progressive disease as defined per RECIST v1.1 or death. RECIST criteria are: * CR = Disappearance of all target lesions * PR = ≥ 30% decrease in the sum of the longest diameter of target lesions * Overall Response (OR) = CR + PR * Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions, and/or the appearance of one or more new lesion(s) * Stable disease (SD) = Small changes that do not meet any of the above criteria
Time frame: up to 9 months
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Cohort 1: Infigratinib (100mg) + Tamoxifen | Progression-free Survival (PFS) | 61 days | Standard Deviation 5.3 |
| Cohort 2: Infigratinib (125mg) + Tamoxifen | Progression-free Survival (PFS) | NA days | — |